Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections

Journal of Clinical Virology

Volumn 82, Issue , 2016, Pages 46-50

  Jentschke, M ^a   Chen, K ^a,b   Arbyn, M ^c   Hertel, B ^a   Noskowicz, M ^a   Soergel, P ^a   Hillemanns, P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TONGJI UNIVERSITY   (China)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cervical cancer screening; Human papillomavirus; Self sampling

Indexed keywords

HEMOGLOBIN BETA CHAIN;

ADENOCARCINOMA IN SITU; ARTICLE; CERVICOVAGINAL SELF-SAMPLING DEVICE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; DEVICES; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PROCEDURES; QUESTIONNAIRE; SELF EXAMINATION; SPECIMEN HANDLING; VAGINA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; SELF-EXAMINATION; SPECIMEN HANDLING; SURVEYS AND QUESTIONNAIRES; VAGINA; YOUNG ADULT;

EID: 84978249321     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.06.016     Document Type: Article

References (34)

1. [1] Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999), 12–19.
2. [2] Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
3. [3] Arbyn, M., Ronco, G., Anttila, A., Meijer, C.J., Poljak, M., Ogilvie, G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl 5 (2012), F88–99.
4. [4] M. Arbyn, A. Haelens, A. Desomer, F. Verdoodt, J. Francart, N. Thiry, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening. KCE Belgian Healthcare Knowledge Centre; 2015.
5. [5] Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA. Cancer J. Clin. 62 (2012), 147–172.
6. [6] Medical Services Advisory Committee (MSAC). Application No. 1276–Renewal of the National Cervical Screening Program. Australian government, department of health; 2014.
7. [7] Elfstrom, K.M., Arnheim-Dahlstrom, L., von Karsa, L., Dillner, J., Cervical cancer screening in Europe: quality assurance and organisation of programmes. Eur. J. Cancer 51 (2015), 950–968.
8. [8] Geyer, S., Jaunzeme, J., Hillemanns, P., Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Arch. Gynecol. Obstet. 291 (2014), 623–629.
9. [9] Marquardt, K., Buttner, H.H., Broschewitz, U., Barten, M., Schneider, V., Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. Acta Cytol. 55 (2011), 433–437.
10. [10] Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J. Natl. Cancer Inst. 100 (2008), 622–629.
11. [11] Leyden, W.A., Manos, M.M., Geiger, A.M., Weinmann, S., Mouchawar, J., Bischoff, K., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J. Natl. Cancer Inst. 97 (2005), 675–683.
12. [12] Sung, H.Y., Kearney, K.A., Miller, M., Kinney, W., Sawaya, G.F., Hiatt, R.A., Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 88 (2000), 2283–2289.
13. [13] Zaal, A., de Wilde, M.A., Duk, M.J., Graziosi, G.C., van Haaften, M., von Mensdorff-Pouilly, S., et al. The diagnostic process of cervical cancer; areas of good practice, and windows of opportunity. Gynecol. Oncol. 138 (2015), 405–410.
14. [14] Arbyn, M., Castle, P.E., Offering self-Sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol. Biomarkers Prev. 24 (2015), 769–772.
15. [15] Arbyn, M., Verdoodt, F., Snijders, P.J., Verhoef, V.M., Suonio, E., Dillner, L., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 15 (2014), 172–183.
16. [16] Richart, R.M., Cervical intraepithelial neoplasia. Pathol. Annu. 8 (1973), 301–328.
17. [17] Poljak, M., Ostrbenk, A., The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol. Alp Pannonica Adriat. 22 (2013), 43–47.
18. [18] Arbyn, M., Snijders, P.J., Meijer, C.J., Berkhof, J., Cuschieri, K., Kocjan, B.J., Poljak, M., Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. 21 (2015), 817–826.
19. [19] Jentschke, M., Soergel, P., Lange, V., Kocjan, B., Doerk, T., Luyten, A., et al. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population. Int. J. Gynecol. Cancer 22 (2012), 1050–1056.
20. [20] Jentschke, M., Soergel, P., Hillemanns, P., Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples. J. Virol Methods 193 (2013), 131–134.
21. [21] Fleiss, J.L., Statistical Methods for Rates and Proportions. 2 ed., 1981, John Wiley & Sons, New York.
22. [22] Jentschke, M., Hillemanns, P., Prävention des Zervixkarzinoms. Das wird die neue S3-Leitlinie berücksichtigen. gynäkologie + geburtshilfe 17 (2012), 22–25.
23. [23] Verdoodt, F., Jentschke, M., Hillemanns, P., Racey, C.S., Snijders, P.J., Arbyn, M., Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer 51 (2015), 2375–2385.
24. [24] Gök, M., Heideman, D.A., van Kemenade, F.J., Berkhof, J., Rozendaal, L., Spruyt, J.W., et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ, 340, 2010, c1040.
25. [25] Hillemanns, P., Kimmig, R., Huttemann, U., Dannecker, C., Thaler, C.J., Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet, 354, 1999, 1970.
26. [26] Igidbashian, S., Boveri, S., Spolti, N., Radice, D., Sandri, M.T., Sideri, M., Self-collected human papillomavirus testing acceptability: comparison of two self-sampling modalities. J. Womens Health (Larchmt) 20 (2011), 397–402.
27. [27] Bosgraaf, R.P., Verhoef, V.M., Massuger, L.F., Siebers, A.G., Bulten, J., de Kuyper-de Ridder, G.M., et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int. J. Cancer 136 (2014), 646–655.
28. [28] van Baars, R., Bosgraaf, R.P., ter Harmsel, B.W., Melchers, W.J., Quint, W.G., Bekkers, R.L., Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. J. Clin. Microbiol. 50 (2012), 3937–3943.
29. [29] Sanner, K., Wikstrom, I., Strand, A., Lindell, M., Wilander, E., Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br. J. Cancer 101 (2009), 871–874.
30. [30] Stenvall, H., Wikstrom, I., Wilander, E., High prevalence of oncogenic human papilloma virus in women not attending organized cytological screening. Acta Derm. Venereol. 87 (2007), 243–245.
31. [31] Wikstrom, I., Lindell, M., Sanner, K., Wilander, E., Self-sampling and HPV testing or ordinary pap-smear in women not regularly attending screening: a randomised study. Br. J. Cancer 105 (2011), 337–339.
32. [32] Gyllensten, U., Sanner, K., Gustavsson, I., Lindell, M., Wikstrom, I., Wilander, E., Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br. J. Cancer 105 (2011), 694–697.
33. [33] Lindell, M., Sanner, K., Wikstrom, I., Wilander, E., Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG 119 (2012), 245–248.
34. [34] Stenvall, H., Wikstrom, I., Wilander, E., Human papilloma virus testing of vaginal smear obtained with a novel self-sampling device. Acta Derm. Venereol. 86 (2006), 465–467.